Scholarlink

Background <p>The comparative efficacy of tenecteplase versus alteplase in achieving early recanalization (ER) before mechanical thrombectomy (MT) for large-vessel occlusion (LVO) remains uncertain.</p> Methods <p>This study was a retrospective analysis of prospectively collected data of consecutive patients with LVO underwent intravenous thrombolysis (IVT) and brain angiography between January 2022 and December 2023. ER was defined as ≥ 50% reperfusion or absence of retrievable thrombus on initial angiography.</p> Results <p>146 patients received tenecteplase and 307 received alteplase. Tenecteplase shortened door-to-IVT time (33 vs. 39 min,&#xa0;<i>P</i> &lt; 0.001) and door-to-puncture time (97 vs. 109 min,&#xa0;<i>P</i> = 0.039) compared to alteplase. Overall ER rates did not differ significantly (17.1% vs. 12.1%,&#xa0;<i>P</i> = 0.223). However, a significant interaction was observed between thrombolytic agent and IVT-to-puncture time (<i>P</i><sub>interaction</sub> = 0.034): tenecteplase achieved higher ER rates when IVT-to-puncture time was &lt; 60 min (17.2% vs. 5.0%, aOR, 4.13 [95% CI 1.24–13.74]). With IVT-to-puncture time ≥ 60 min, ER rates were similar (17.2% vs. 16.8%, aOR 0.91 [95% CI 0.43–1.91]). No ER differences were noted across occlusion sites, clot burden, NIHSS, sex, and age. At 3&#xa0;months, tenecteplase reduced disability rates (mRS 0–3: 73.5% vs. 65.7%, <i>P</i> = 0.041). Functional independence (mRS 0–2) was 57.4% with tenecteplase and 53.1% with alteplase (<i>P</i> = 0.301).</p> Conclusions <p>Real-world observations reveal tenecteplase has increased ER rates compared to alteplase within 1&#xa0;h of IVT and reduced disability in LVO patients. Further randomized trials are warranted to evaluate the effect of tenecteplase rapid bridging mechanical thrombectomy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Tenecteplase compared to alteplase before mechanical thrombectomy enhances 1-h recanalization and reduces disability in large-vessel occlusion

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月9日

查看全文
  • Lu Wang,
  • Jialu Li,
  • Xiao Wu,
  • Lulan Li,
  • Xueqiao Jiao,
  • Fengyuan Che,
  • Hongxing Han,
  • Liyong Zhang,
  • Weidong Liu,
  • Peifu Wang,
  • Fuxia Yang,
  • Fangfang Zhang,
  • Xunming Ji,
  • Xiuhai Guo

摘要

Background

The comparative efficacy of tenecteplase versus alteplase in achieving early recanalization (ER) before mechanical thrombectomy (MT) for large-vessel occlusion (LVO) remains uncertain.

Methods

This study was a retrospective analysis of prospectively collected data of consecutive patients with LVO underwent intravenous thrombolysis (IVT) and brain angiography between January 2022 and December 2023. ER was defined as ≥ 50% reperfusion or absence of retrievable thrombus on initial angiography.

Results

146 patients received tenecteplase and 307 received alteplase. Tenecteplase shortened door-to-IVT time (33 vs. 39 min, P < 0.001) and door-to-puncture time (97 vs. 109 min, P = 0.039) compared to alteplase. Overall ER rates did not differ significantly (17.1% vs. 12.1%, P = 0.223). However, a significant interaction was observed between thrombolytic agent and IVT-to-puncture time (Pinteraction = 0.034): tenecteplase achieved higher ER rates when IVT-to-puncture time was < 60 min (17.2% vs. 5.0%, aOR, 4.13 [95% CI 1.24–13.74]). With IVT-to-puncture time ≥ 60 min, ER rates were similar (17.2% vs. 16.8%, aOR 0.91 [95% CI 0.43–1.91]). No ER differences were noted across occlusion sites, clot burden, NIHSS, sex, and age. At 3 months, tenecteplase reduced disability rates (mRS 0–3: 73.5% vs. 65.7%, P = 0.041). Functional independence (mRS 0–2) was 57.4% with tenecteplase and 53.1% with alteplase (P = 0.301).

Conclusions

Real-world observations reveal tenecteplase has increased ER rates compared to alteplase within 1 h of IVT and reduced disability in LVO patients. Further randomized trials are warranted to evaluate the effect of tenecteplase rapid bridging mechanical thrombectomy.